Corvus Pharmaceuticals, Inc. Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax
Corvus Pharmaceuticals, Inc. (CRVS) had Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax of $41.00 thousand as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2018-03-01
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $41.00K.
- 2017-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $15.00K.
- 2017-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $50.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2017-12-31 | $41.00K 10-K · filed 2018-03-01 |
| 2017-09-30 | $15.00K 10-Q · filed 2017-11-02 |
| 2017-06-30 | $50.00K 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |